Detalles de la búsqueda
1.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Lancet Oncol
; 24(7): 744-756, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37329891
2.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Lancet
; 388(10043): 488-97, 2016 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27291997
3.
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Eur J Cancer
; 107: 186-195, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573277
4.
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Lung Cancer
; 111: 108-115, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28838379
5.
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Cancer Chemother Pharmacol
; 78(4): 815-24, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27566701
6.
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 73(3): 595-604, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24452395
Resultados
1 -
6
de 6
1
Próxima >
>>